midazolam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
diazepam derivatives	1802	59467-70-8

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: buccolam midazolam mezolam midazolam hydrochloride midazolam HCl

A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Molecular weight: 325.77 Formula: C18H13ClFN3 CLOGP: 3.42 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 30.18 ALOGS: -4.52 ROTB: 1 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
5	mg	N
15	mg	O
15	mg	P
10	mg	SL

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10.30 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	5.60 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.26 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	44 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.10 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	5.30 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	3.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Dec. 20, 1985	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	471.39	13.75	208	27464	13771	46644619
Hypotension	246.32	13.75	470	27202	232119	46426271
Anaphylactic reaction	239.86	13.75	220	27452	52892	46605498
Cardiac arrest	230.90	13.75	276	27396	90123	46568267
Serotonin syndrome	221.38	13.75	152	27520	24068	46634322
Propofol infusion syndrome	179.95	13.75	49	27623	732	46657658
Drug interaction	163.59	13.75	367	27305	202727	46455663
Seizure	157.03	13.75	270	27402	122784	46535606
Fatigue	154.30	13.75	85	27587	608612	46049778
Anaphylactic shock	152.44	13.75	113	27559	20161	46638229
Generalised tonic-clonic seizure	145.61	13.75	124	27548	26998	46631392
Respiratory acidosis	140.60	13.75	70	27602	6078	46652312
Tachycardia	139.59	13.75	228	27444	99394	46558996
Multiple organ dysfunction syndrome	137.02	13.75	161	27511	51549	46606841
Multiple-drug resistance	126.22	13.75	50	27622	2515	46655875
Delayed recovery from anaesthesia	122.03	13.75	37	27635	824	46657566
Bradycardia	121.55	13.75	172	27500	66126	46592264
Anaesthetic complication	120.35	13.75	44	27628	1773	46656617
Labile blood pressure	104.55	13.75	39	27633	1664	46656726
Agitation	103.39	13.75	145	27527	55270	46603120
Drug ineffective	102.47	13.75	718	26954	677120	45981270
Circulatory collapse	102.26	13.75	92	27580	21532	46636858
Diabetes insipidus	102.18	13.75	41	27631	2133	46656257
Diarrhoea	95.73	13.75	115	27557	559487	46098903
Unwanted awareness during anaesthesia	94.23	13.75	24	27648	272	46658118
Unresponsive to stimuli	93.32	13.75	105	27567	32069	46626321
Delirium	87.31	13.75	109	27563	37119	46621271
Nausea	86.41	13.75	174	27498	687280	45971110
Fall	85.96	13.75	44	27628	329053	46329337
Respiratory depression	85.71	13.75	64	27608	11536	46646854
Drug ineffective for unapproved indication	83.93	13.75	73	27599	16340	46642050
Pulseless electrical activity	82.54	13.75	52	27620	7115	46651275
Metabolic acidosis	82.22	13.75	108	27564	38672	46619718
Headache	82.05	13.75	98	27574	478254	46180136
Myoclonus	81.92	13.75	68	27604	14284	46644106
Renal ischaemia	81.56	13.75	25	27647	578	46657812
Shock	78.72	13.75	80	27592	21765	46636625
Mitochondrial DNULL mutation	78.18	13.75	20	27652	231	46658159
Respiratory failure	76.84	13.75	172	27500	94644	46563746
Joint swelling	75.81	13.75	6	27666	166067	46492323
Neuromuscular block prolonged	75.40	13.75	23	27649	523	46657867
Encephalopathy	75.04	13.75	96	27576	33493	46624897
Partial seizures	74.93	13.75	43	27629	4967	46653423
Arthralgia	73.43	13.75	65	27607	364538	46293852
Oxygen saturation decreased	73.12	13.75	140	27532	69024	46589366
Intestinal ischaemia	71.73	13.75	47	27625	6878	46651512
Apnoea	71.63	13.75	48	27624	7291	46651099
Alopecia	68.51	13.75	8	27664	162406	46495984
Pain in extremity	68.37	13.75	34	27638	258646	46399744
Cardiogenic shock	68.34	13.75	65	27607	16319	46642071
Anticholinergic syndrome	67.76	13.75	29	27643	1777	46656613
Procedural complication	67.61	13.75	40	27632	4890	46653500
Anaesthetic complication neurological	67.54	13.75	17	27655	183	46658207
Bronchospasm	66.82	13.75	63	27609	15644	46642746
Blood pH decreased	66.31	13.75	32	27640	2595	46655795
Intra-abdominal pressure increased	65.93	13.75	17	27655	203	46658187
Disseminated intravascular coagulation	63.78	13.75	67	27605	18938	46639452
Electroencephalogram abnormal	63.69	13.75	35	27637	3719	46654671
PCO2 increased	63.64	13.75	25	27647	1229	46657161
Malaise	63.19	13.75	62	27610	331170	46327220
Pneumatosis	63.18	13.75	19	27653	411	46657979
Oxygen saturation abnormal	62.30	13.75	31	27641	2687	46655703
PO2 increased	60.61	13.75	22	27650	868	46657522
Abdominal discomfort	60.03	13.75	9	27663	151156	46507234
Stress cardiomyopathy	59.87	13.75	44	27628	7740	46650650
Hypoxia	59.86	13.75	109	27563	51729	46606661
Methaemoglobinaemia	59.65	13.75	28	27644	2134	46656256
Procedural hypotension	57.64	13.75	23	27649	1179	46657211
Renal impairment	56.99	13.75	132	27540	74240	46584150
Pain	56.14	13.75	125	27547	476823	46181567
Acute respiratory distress syndrome	54.31	13.75	66	27606	21856	46636534
Mydriasis	54.07	13.75	47	27625	10506	46647884
Electrocardiogram QRS complex prolonged	54.05	13.75	36	27636	5413	46652977
Electrocardiogram ST segment elevation	53.36	13.75	31	27641	3664	46654726
Product dose omission issue	52.91	13.75	17	27655	168503	46489887
Sinus tachycardia	51.72	13.75	64	27608	21585	46636805
Ventricular hypokinesia	50.53	13.75	31	27641	4047	46654343
Ventricular tachycardia	50.25	13.75	56	27616	16911	46641479
Peripheral swelling	49.52	13.75	16	27656	158055	46500335
Foetal death	49.01	13.75	41	27631	8702	46649688
Ventricular extrasystoles	48.26	13.75	45	27627	11018	46647372
Electrocardiogram ST segment depression	48.16	13.75	26	27646	2667	46655723
Drug intolerance	47.66	13.75	14	27658	147035	46511355
Depressed level of consciousness	47.46	13.75	94	27578	47475	46610915
Dizziness	47.11	13.75	81	27591	340333	46318057
Necrosis ischaemic	46.98	13.75	18	27654	827	46657563
Gene mutation	46.07	13.75	19	27653	1061	46657329
Blood lactic acid increased	45.83	13.75	33	27639	5624	46652766
Anaesthetic complication pulmonary	45.79	13.75	10	27662	54	46658336
Weight decreased	45.58	13.75	35	27637	210814	46447576
Epilepsy	45.56	13.75	63	27609	23675	46634715
Systemic inflammatory response syndrome	45.05	13.75	32	27640	5339	46653051
Blood gases abnormal	44.30	13.75	16	27656	622	46657768
Nasopharyngitis	44.15	13.75	18	27654	153980	46504410
Kounis syndrome	44.11	13.75	19	27653	1183	46657207
Epileptic aura	43.94	13.75	10	27662	67	46658323
Renal injury	43.93	13.75	40	27632	9501	46648889
Fear	43.87	13.75	51	27621	16121	46642269
Blood bicarbonate decreased	43.78	13.75	25	27647	2860	46655530
Upper airway obstruction	43.03	13.75	15	27657	525	46657865
Hyperaesthesia	42.30	13.75	36	27636	7820	46650570
Hepatic failure	42.08	13.75	73	27599	33343	46625047
Perforation	40.87	13.75	17	27655	970	46657420
Hypoventilation	40.39	13.75	27	27645	4083	46654307
Hepatic ischaemia	40.11	13.75	14	27658	492	46657898
Non-consummation	39.08	13.75	9	27663	64	46658326
Anorectal ulcer	39.08	13.75	9	27663	64	46658326
Haemodynamic instability	38.76	13.75	34	27638	7691	46650699
Cardiotoxicity	38.67	13.75	32	27640	6690	46651700
Pseudopolyp	37.16	13.75	11	27661	225	46658165
Blood pressure decreased	36.90	13.75	95	27577	57064	46601326
Blood creatine phosphokinase increased	36.80	13.75	62	27610	27662	46630728
Post procedural complication	36.77	13.75	46	27626	15683	46642707
Swelling	36.59	13.75	14	27658	124497	46533893
Arthropathy	36.12	13.75	4	27668	84696	46573694
Psoriasis	35.40	13.75	3	27669	78601	46579789
Restlessness	35.11	13.75	58	27614	25466	46632924
Unmasking of previously unidentified disease	35.09	13.75	14	27658	717	46657673
Brain oedema	34.93	13.75	40	27632	12438	46645952
Altered state of consciousness	34.76	13.75	55	27617	23293	46635097
Airway peak pressure increased	34.70	13.75	11	27661	285	46658105
Sinusitis	34.32	13.75	17	27655	129751	46528639
Hepatorenal syndrome	33.86	13.75	18	27654	1790	46656600
Hypernatraemia	33.79	13.75	29	27643	6372	46652018
Airway complication of anaesthesia	33.67	13.75	10	27662	207	46658183
Coma	33.64	13.75	93	27579	58256	46600134
Clonus	33.51	13.75	24	27648	4056	46654334
Diabetic macroangiopathy	33.14	13.75	9	27663	133	46658257
Septic shock	33.11	13.75	92	27580	57801	46600589
Back pain	32.81	13.75	46	27626	209993	46448397
Myalgia	32.74	13.75	16	27656	123072	46535318
Laryngeal stenosis	32.38	13.75	13	27659	677	46657713
Weight increased	32.21	13.75	30	27642	164443	46493947
Sinus bradycardia	31.73	13.75	40	27632	13742	46644648
Hepatocellular injury	31.47	13.75	60	27612	29462	46628928
Asthenia	31.46	13.75	88	27584	310987	46347403
Muscle rigidity	31.44	13.75	34	27638	9927	46648463
Oliguria	31.40	13.75	32	27640	8727	46649663
Bronchitis	31.00	13.75	12	27660	105967	46552423
Toxicity to various agents	30.85	13.75	223	27449	211543	46446847
Left ventricular dysfunction	30.63	13.75	34	27638	10221	46648169
Infusion related reaction	30.37	13.75	11	27661	101197	46557193
Systolic dysfunction	30.15	13.75	15	27657	1299	46657091
Product administered to patient of inappropriate age	29.64	13.75	19	27653	2677	46655713
Encephalitis autoimmune	29.30	13.75	14	27658	1110	46657280
Muscle relaxant therapy	29.28	13.75	8	27664	121	46658269
Therapeutic product effect prolonged	29.16	13.75	10	27662	333	46658057
Gastrointestinal scarring	29.16	13.75	9	27663	213	46658177
Asthma	29.13	13.75	9	27663	91533	46566857
Ventricular fibrillation	29.10	13.75	35	27637	11461	46646929
Off label use	28.96	13.75	348	27324	379493	46278897
Contusion	28.94	13.75	8	27664	87479	46570911
Renal failure	28.46	13.75	138	27534	113456	46544934
Tachyphylaxis	28.18	13.75	9	27663	239	46658151
Palpitations	27.51	13.75	11	27661	95248	46563142
Ultrasound ovary abnormal	27.43	13.75	7	27665	80	46658310
Acid base balance abnormal	27.43	13.75	9	27663	261	46658129
Pruritus	27.22	13.75	65	27607	242287	46416103
Anhedonia	27.04	13.75	32	27640	10303	46648087
Cardiac arrest neonatal	27.04	13.75	7	27665	85	46658305
Hyperammonaemic encephalopathy	26.96	13.75	16	27656	1966	46656424
Pupils unequal	26.93	13.75	14	27658	1330	46657060
Urinary tract infection	26.42	13.75	57	27615	220209	46438181
Rhabdomyolysis	26.37	13.75	69	27603	41840	46616550
Influenza	26.29	13.75	10	27662	89260	46569130
Sedation	26.21	13.75	48	27624	22862	46635528
Laryngospasm	26.15	13.75	18	27654	2855	46655535
Musculoskeletal stiffness	25.66	13.75	13	27659	97980	46560410
Patent ductus arteriosus	25.65	13.75	20	27652	3842	46654548
Abdominal pain upper	25.62	13.75	29	27643	145276	46513114
Systemic lupus erythematosus	25.58	13.75	4	27668	65176	46593214
Acidosis hyperchloraemic	25.39	13.75	9	27663	331	46658059
Tryptase increased	25.32	13.75	8	27664	205	46658185
Hypoaesthesia	25.32	13.75	20	27652	118849	46539541
Pituitary apoplexy	25.25	13.75	7	27665	112	46658278
Atrioventricular dissociation	24.89	13.75	8	27664	217	46658173
Wrong product administered	24.74	13.75	23	27649	5607	46652783
Arrhythmia	24.67	13.75	60	27612	34781	46623609
Bulimia nervosa	24.65	13.75	10	27662	535	46657855
Gait disturbance	24.53	13.75	30	27642	145233	46513157
Anuria	24.47	13.75	32	27640	11399	46646991
Respiratory rate increased	24.46	13.75	32	27640	11401	46646989
Post procedural stroke	24.33	13.75	6	27666	59	46658331
Paradoxical drug reaction	24.30	13.75	16	27656	2360	46656030
Neurotoxicity	24.23	13.75	35	27637	13682	46644708
Injection site pain	24.15	13.75	17	27655	107135	46551255
Hypotonia	24.09	13.75	27	27645	8202	46650188
Carcinoid crisis	24.06	13.75	8	27664	242	46658148
Exposure during pregnancy	23.97	13.75	127	27545	108085	46550305
Incorrect route of product administration	23.57	13.75	38	27634	16345	46642045
Myoglobin blood increased	23.29	13.75	13	27659	1423	46656967
Drug reaction with eosinophilia and systemic symptoms	23.22	13.75	53	27619	29495	46628895
Syncope	23.13	13.75	17	27655	104786	46553604
Gastrointestinal mucosa hyperaemia	22.67	13.75	7	27665	166	46658224
Cough	22.62	13.75	66	27606	230183	46428207
Acute hepatic failure	22.36	13.75	35	27637	14686	46643704
Muscle spasms	22.33	13.75	24	27648	123089	46535301
Neonatal seizure	22.25	13.75	8	27664	307	46658083
Infection parasitic	22.25	13.75	8	27664	307	46658083
Overdose	22.12	13.75	119	27553	101860	46556530
Drug tolerance	22.10	13.75	17	27655	3201	46655189
Electrocardiogram repolarisation abnormality	22.03	13.75	12	27660	1253	46657137
Procedural vomiting	21.90	13.75	9	27663	498	46657892
Contraindicated product administered	21.85	13.75	10	27662	79937	46578453
Ventricular dysfunction	21.76	13.75	16	27656	2816	46655574
Constipation	21.75	13.75	44	27628	174053	46484337
Coronary artery embolism	21.60	13.75	7	27665	195	46658195
Dyspnoea	21.43	13.75	199	27473	515349	46143041
White blood cell count decreased	21.35	13.75	21	27651	112210	46546180
Pulse absent	21.31	13.75	20	27652	4936	46653454
Hyperthermia	21.28	13.75	25	27647	7989	46650401
Intensive care unit delirium	21.20	13.75	5	27667	40	46658350
Pneumothorax	21.14	13.75	34	27638	14595	46643795
Eosinophilic pneumonia acute	21.10	13.75	8	27664	357	46658033
Acute coronary syndrome	20.97	13.75	28	27644	10176	46648214
Rash	20.82	13.75	125	27547	356387	46302003
Tonsillar hypertrophy	20.68	13.75	10	27662	814	46657576
Pulmonary oedema	20.66	13.75	72	27600	51033	46607357
Loss of consciousness	20.63	13.75	122	27550	108116	46550274
Electrocardiogram QT prolonged	20.48	13.75	72	27600	51253	46607137
Musculoskeletal pain	20.40	13.75	8	27664	70120	46588270
Hyperammonaemia	20.21	13.75	19	27653	4697	46653693
Intensive care unit acquired weakness	19.87	13.75	9	27663	632	46657758
Dyschezia	19.63	13.75	12	27660	1556	46656834
Oedema peripheral	19.41	13.75	41	27631	159665	46498725
Drug resistance	19.38	13.75	36	27636	17332	46641058
Dehydration	19.35	13.75	41	27631	159499	46498891
Blood magnesium decreased	19.35	13.75	28	27644	10964	46647426
Chest pain	19.22	13.75	48	27624	176276	46482114
C-reactive protein decreased	19.17	13.75	9	27663	686	46657704
Hypertonia	19.16	13.75	18	27654	4448	46653942
Colitis	19.07	13.75	57	27615	37290	46621100
Delayed graft function	19.07	13.75	10	27662	967	46657423
Apnoeic attack	19.03	13.75	7	27665	287	46658103
Nephrocalcinosis	18.97	13.75	10	27662	977	46657413
Euthyroid sick syndrome	18.86	13.75	5	27667	67	46658323
Anaphylactoid shock	18.78	13.75	7	27665	298	46658092
Cholestasis	18.71	13.75	46	27626	26847	46631543
Sinus arrest	18.54	13.75	12	27660	1719	46656671
Hyperthermia malignant	18.53	13.75	9	27663	740	46657650
Neuromuscular blockade	18.37	13.75	7	27665	317	46658073
Acute respiratory failure	18.35	13.75	48	27624	29090	46629300
Drug-induced liver injury	18.30	13.75	44	27628	25324	46633066
Dry mouth	18.20	13.75	5	27667	54921	46603469
Opisthotonus	18.10	13.75	7	27665	330	46658060
Paralysis	18.02	13.75	24	27648	8697	46649693
Decreased appetite	18.00	13.75	57	27615	193779	46464611
Gastrooesophageal reflux disease	17.82	13.75	11	27661	74333	46584057
Herpes zoster	17.77	13.75	9	27663	67863	46590527
Granulomatous liver disease	17.69	13.75	9	27663	817	46657573
Respiratory arrest	17.64	13.75	52	27620	33764	46624626
White matter lesion	17.62	13.75	10	27662	1131	46657259
Immunosuppressant drug level increased	17.59	13.75	15	27657	3267	46655123
Acidosis	17.57	13.75	27	27645	11147	46647243
Left ventricular hypertrophy	17.55	13.75	18	27654	4945	46653445
Symptom masked	17.52	13.75	8	27664	572	46657818
Agitation postoperative	17.43	13.75	4	27668	28	46658362
Gastrointestinal vascular malformation	17.43	13.75	4	27668	28	46658362
Breast cancer	17.40	13.75	3	27669	45515	46612875
Torsade de pointes	17.22	13.75	28	27644	12126	46646264
Product contamination microbial	16.87	13.75	6	27666	223	46658167
Cardiac output decreased	16.85	13.75	9	27663	903	46657487
Abdominal rigidity	16.77	13.75	11	27661	1611	46656779
Foetal exposure during pregnancy	16.73	13.75	48	27624	30699	46627691
Jaundice acholuric	16.68	13.75	5	27667	107	46658283
Maternal exposure during pregnancy	16.68	13.75	111	27561	102438	46555952
Cardio-respiratory arrest	16.64	13.75	75	27597	59794	46598596
Rash morbilliform	16.63	13.75	14	27658	2995	46655395
Hypertrophic cardiomyopathy	16.52	13.75	10	27662	1274	46657116
Injection site erythema	16.51	13.75	12	27660	74415	46583975
Cardiac failure congestive	16.50	13.75	18	27654	91732	46566658
Gaze palsy	16.42	13.75	10	27662	1288	46657102
Posterior reversible encephalopathy syndrome	16.41	13.75	31	27641	15110	46643280
Stevens-Johnson syndrome	16.36	13.75	40	27632	23257	46635133
Tachypnoea	16.33	13.75	30	27642	14321	46644069
Neuroleptic malignant syndrome	16.28	13.75	26	27646	11096	46647294
Leukocytosis	16.25	13.75	40	27632	23358	46635032
Myocardial ischaemia	16.24	13.75	28	27644	12721	46645669
Epileptic encephalopathy	16.19	13.75	6	27666	251	46658139
Large intestinal ulcer	16.12	13.75	14	27658	3125	46655265
Product use in unapproved indication	16.08	13.75	100	27572	90173	46568217
Bone pain	16.05	13.75	4	27668	46886	46611504
Selective eating disorder	16.04	13.75	11	27661	1734	46656656
Cellulitis	16.03	13.75	11	27661	70277	46588113
Sleep disorder	16.00	13.75	4	27668	46791	46611599
Mobility decreased	15.92	13.75	8	27664	60586	46597804
Ileus paralytic	15.87	13.75	16	27656	4307	46654083
Female genital tract fistula	15.74	13.75	14	27658	3225	46655165
Respiratory distress	15.63	13.75	48	27624	31868	46626522
Device related sepsis	15.56	13.75	14	27658	3273	46655117
Haemodialysis	15.53	13.75	23	27649	9194	46649196
Supraventricular tachycardia	15.43	13.75	28	27644	13242	46645148
Hypochloraemia	15.34	13.75	11	27661	1862	46656528
Infantile apnoea	15.31	13.75	8	27664	768	46657622
Feeling abnormal	15.28	13.75	32	27640	125028	46533362
Stomatitis	15.17	13.75	11	27661	68286	46590104
Resuscitation	15.14	13.75	9	27663	1110	46657280
Foetal growth restriction	15.02	13.75	19	27653	6548	46651842
Hyperreflexia	14.97	13.75	17	27655	5237	46653153
Enzyme induction	14.93	13.75	4	27668	56	46658334
Tracheal injury	14.93	13.75	4	27668	56	46658334
Oxygen saturation immeasurable	14.90	13.75	3	27669	10	46658380
Chest discomfort	14.86	13.75	19	27653	90250	46568140
Weaning failure	14.83	13.75	6	27666	319	46658071
Drug level abnormal	14.80	13.75	4	27668	58	46658332
Manipulation	14.80	13.75	4	27668	58	46658332
Drug chemical incompatibility	14.80	13.75	4	27668	58	46658332
Burning sensation	14.80	13.75	4	27668	44407	46613983
Migraine	14.63	13.75	12	27660	70014	46588376
Rhinorrhoea	14.60	13.75	5	27667	47660	46610730
Pseudomonas infection	14.54	13.75	23	27649	9735	46648655
Influenza like illness	14.53	13.75	8	27664	57562	46600828
Blood cholesterol increased	14.52	13.75	3	27669	40010	46618380
Teratoma	14.48	13.75	5	27667	170	46658220
Conjunctival oedema	14.38	13.75	7	27665	578	46657812
Loss of personal independence in daily activities	14.36	13.75	8	27664	57175	46601215
Hot flush	14.35	13.75	4	27668	43513	46614877
Atrioventricular block first degree	14.31	13.75	18	27654	6168	46652222
Blood creatine phosphokinase MB increased	14.14	13.75	9	27663	1252	46657138
Acute kidney injury	14.13	13.75	207	27465	235648	46422742
Febrile infection-related epilepsy syndrome	14.10	13.75	3	27669	14	46658376
Blood methaemoglobin present	14.10	13.75	4	27668	70	46658320
Coma hepatic	14.04	13.75	7	27665	609	46657781
Spontaneous haemorrhage	14.03	13.75	5	27667	187	46658203
Catatonia	13.95	13.75	14	27658	3748	46654642
Local anaesthetic systemic toxicity	13.95	13.75	6	27666	372	46658018
Ammonia increased	13.92	13.75	15	27657	4362	46654028
Vocal cord dysfunction	13.85	13.75	5	27667	194	46658196
Acute generalised exanthematous pustulosis	13.78	13.75	22	27650	9383	46649007

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Status epilepticus	301.11	12.73	164	27613	10908	29913793
Anaphylactic reaction	224.75	12.73	195	27582	27787	29896914
Hypotension	221.68	12.73	538	27239	200027	29724674
Serotonin syndrome	194.97	12.73	149	27628	17742	29906959
Hyperthermia malignant	155.56	12.73	60	27717	1774	29922927
Propofol infusion syndrome	153.29	12.73	49	27728	817	29923884
Fatigue	136.06	12.73	64	27713	320609	29604092
Cardiac arrest	135.78	12.73	279	27498	92571	29832130
Bradycardia	122.98	12.73	219	27558	65307	29859394
Sedation	119.22	12.73	108	27669	16265	29908436
Seizure	110.26	12.73	266	27511	98209	29826492
Metabolic acidosis	108.82	12.73	153	27624	37308	29887393
Anaphylactic shock	107.22	12.73	95	27682	13898	29910803
Multiple organ dysfunction syndrome	102.59	12.73	199	27578	63288	29861413
Respiratory depression	102.18	12.73	85	27692	11418	29913283
Tachycardia	94.36	12.73	210	27567	73529	29851172
Delirium	91.01	12.73	147	27630	40484	29884217
Drug ineffective	89.17	12.73	579	27198	339808	29584893
Diarrhoea	87.70	12.73	109	27668	333994	29590707
Anaesthetic complication	87.20	12.73	34	27743	1035	29923666
Dizziness	87.04	12.73	36	27741	194873	29729828
Agitation	86.73	12.73	169	27608	53904	29870797
Rhabdomyolysis	81.24	12.73	181	27596	63399	29861302
Respiratory failure	78.50	12.73	238	27539	100404	29824297
Coma	76.86	12.73	136	27641	40313	29884388
Intensive care unit acquired weakness	72.07	12.73	28	27749	844	29923857
Delayed recovery from anaesthesia	70.21	12.73	26	27751	685	29924016
Brain oedema	69.82	12.73	71	27706	12327	29912374
Post procedural complication	67.58	12.73	68	27709	11658	29913043
Acute respiratory distress syndrome	66.84	12.73	95	27682	23377	29901324
Haemodynamic instability	66.59	12.73	57	27720	7958	29916743
Hypoxia	66.54	12.73	141	27636	47713	29876988
Product dose omission issue	65.93	12.73	5	27772	91626	29833075
Oxygen saturation decreased	65.10	12.73	132	27645	43308	29881393
Apnoea	63.52	12.73	50	27727	6208	29918493
Arthralgia	62.33	12.73	24	27753	135767	29788934
Procedural complication	61.53	12.73	43	27734	4454	29920247
Generalised tonic-clonic seizure	61.47	12.73	83	27694	19468	29905233
Fear	60.97	12.73	62	27715	10763	29913938
Fall	60.60	12.73	48	27729	181824	29742877
Diabetes insipidus	60.37	12.73	33	27744	2206	29922495
Drug ineffective for unapproved indication	58.90	12.73	61	27716	10819	29913882
Acidosis hyperchloraemic	57.94	12.73	18	27759	272	29924429
Drug reaction with eosinophilia and systemic symptoms	55.67	12.73	97	27680	28391	29896310
Autonomic nervous system imbalance	55.28	12.73	32	27745	2389	29922312
Headache	54.83	12.73	53	27724	182253	29742448
Unresponsive to stimuli	54.31	12.73	92	27685	26327	29898374
Drug interaction	54.15	12.73	343	27434	199225	29725476
Asthenia	53.04	12.73	77	27700	221213	29703488
Necrosis ischaemic	52.76	12.73	16	27761	222	29924479
Pain in extremity	51.37	12.73	19	27758	110202	29814499
Anaesthetic complication neurological	51.35	12.73	17	27760	318	29924383
Respiratory acidosis	50.20	12.73	37	27740	4165	29920536
Myalgia	47.95	12.73	7	27770	76660	29848041
Intestinal ischaemia	47.28	12.73	44	27733	6853	29917848
Seizure like phenomena	46.66	12.73	18	27759	532	29924169
Ventricular fibrillation	45.67	12.73	63	27714	15075	29909626
Dyspnoea	45.48	12.73	158	27619	333137	29591564
Peripheral swelling	44.88	12.73	3	27774	61071	29863630
Shock	44.87	12.73	78	27699	22781	29901920
Multiple-drug resistance	44.68	12.73	30	27747	2911	29921790
Nausea	43.79	12.73	136	27641	296821	29627880
Long QT syndrome	43.33	12.73	27	27750	2306	29922395
Toxic epidermal necrolysis	43.02	12.73	67	27710	17873	29906828
Septic shock	42.75	12.73	143	27634	63464	29861237
Catatonia	42.32	12.73	34	27743	4346	29920355
Blood pressure decreased	42.10	12.73	117	27660	46958	29877743
Brain death	41.55	12.73	27	27750	2479	29922222
Pulseless electrical activity	41.50	12.73	39	27738	6148	29918553
Ventricular tachycardia	41.20	12.73	77	27700	23785	29900916
Death	40.10	12.73	183	27594	357100	29567601
Malaise	40.05	12.73	58	27719	166904	29757797
Product administered to patient of inappropriate age	38.77	12.73	26	27751	2517	29922184
Mucosal ulceration	38.55	12.73	18	27759	860	29923841
Neuromuscular block prolonged	38.31	12.73	14	27763	355	29924346
Kounis syndrome	37.90	12.73	22	27755	1651	29923050
Neuroleptic malignant syndrome	37.88	12.73	60	27717	16235	29908466
Electrocardiogram ST segment elevation	37.73	12.73	32	27745	4410	29920291
Depressed level of consciousness	37.18	12.73	98	27679	38124	29886577
Circulatory collapse	37.13	12.73	67	27710	20147	29904554
Sedation complication	36.31	12.73	17	27760	817	29923884
Superinfection	35.97	12.73	21	27756	1593	29923108
Dehydration	35.86	12.73	37	27740	123502	29801199
Blood lactic acid increased	35.79	12.73	35	27742	5795	29918906
Hypercapnia	35.50	12.73	29	27748	3795	29920906
Decreased appetite	35.05	12.73	53	27724	149857	29774844
Electrocardiogram QT prolonged	34.98	12.73	92	27685	35743	29888958
Hypoventilation	34.72	12.73	26	27751	2997	29921704
Cyanosis	33.52	12.73	48	27729	11887	29912814
Unwanted awareness during anaesthesia	33.41	12.73	8	27769	41	29924660
Hypertransaminasaemia	33.03	12.73	28	27749	3857	29920844
Renal injury	32.69	12.73	47	27730	11682	29913019
Neonatal respiratory depression	32.61	12.73	13	27764	420	29924281
Respiratory arrest	32.61	12.73	79	27698	29179	29895522
Areflexia	32.61	12.73	24	27753	2695	29922006
Joint swelling	32.54	12.73	3	27774	46943	29877758
Emotional distress	32.52	12.73	55	27722	15710	29908991
Injury	32.49	12.73	66	27711	21665	29903036
Dyskinesia	32.27	12.73	66	27711	21768	29902933
Hyperthermia	31.93	12.73	43	27734	10056	29914645
Abdominal discomfort	31.58	12.73	4	27773	48787	29875914
Corneal reflex decreased	31.49	12.73	10	27767	163	29924538
Nasopharyngitis	31.25	12.73	8	27769	58841	29865860
COVID-19 pneumonia	31.19	12.73	29	27748	4511	29920190
Weight decreased	30.99	12.73	58	27719	150863	29773838
Artery dissection	30.72	12.73	9	27768	110	29924591
Trigemino-cardiac reflex	30.65	12.73	9	27768	111	29924590
Anticonvulsant drug level below therapeutic	30.60	12.73	14	27763	638	29924063
Intracranial pressure increased	29.35	12.73	25	27752	3465	29921236
Hyperexplexia	29.06	12.73	7	27770	37	29924664
Laryngospasm	28.68	12.73	17	27760	1326	29923375
Toxicity to various agents	28.61	12.73	270	27507	176913	29747788
Muscle rigidity	28.42	12.73	41	27736	10220	29914481
Acidosis	28.30	12.73	41	27736	10260	29914441
Myoclonus	28.20	12.73	47	27730	13265	29911436
Disseminated intravascular coagulation	28.14	12.73	63	27714	22108	29902593
Myocardial infarction	27.85	12.73	46	27731	125579	29799122
Anaesthetic complication pulmonary	27.60	12.73	6	27771	18	29924683
Pruritus	27.41	12.73	42	27735	118162	29806539
Back pain	27.27	12.73	33	27744	102563	29822138
Hyperammonaemia	26.43	12.73	29	27748	5491	29919210
Renal failure	26.29	12.73	207	27570	128759	29795942
White blood cell count decreased	25.66	12.73	24	27753	83923	29840778
Respiratory distress	24.73	12.73	77	27700	32895	29891806
Arteriospasm coronary	24.61	12.73	20	27757	2598	29922103
Tachypnoea	24.26	12.73	47	27730	14905	29909796
Cardio-respiratory arrest	23.96	12.73	111	27666	57195	29867506
Pupil fixed	23.86	12.73	17	27760	1815	29922886
Drug withdrawal syndrome	23.71	12.73	55	27722	19754	29904947
Oedema peripheral	23.22	12.73	39	27738	105793	29818908
Hepatitis fulminant	22.97	12.73	23	27754	3918	29920783
Hypocapnia	22.96	12.73	7	27770	99	29924602
Anhedonia	22.54	12.73	33	27744	8336	29916365
Plasma cell myeloma	22.04	12.73	11	27766	53451	29871250
Epilepsy	21.98	12.73	54	27723	20115	29904586
Coagulopathy	21.76	12.73	51	27726	18436	29906265
Shoshin beriberi	21.76	12.73	6	27771	58	29924643
Hospitalisation	21.73	12.73	7	27770	44312	29880389
Stress cardiomyopathy	21.63	12.73	15	27762	1534	29923167
Hyperammonaemic encephalopathy	21.49	12.73	16	27761	1828	29922873
Dystonia	21.49	12.73	35	27742	9692	29915009
Off label use	21.39	12.73	337	27440	248953	29675748
Chronic obstructive pulmonary disease	21.39	12.73	8	27769	46118	29878583
Tryptase increased	21.35	12.73	8	27769	218	29924483
Haemophagocytic lymphohistiocytosis	21.32	12.73	35	27742	9756	29914945
Anaemia	21.23	12.73	110	27667	207882	29716819
Nystagmus	21.13	12.73	23	27754	4315	29920386
Hyperaesthesia	21.10	12.73	21	27756	3552	29921149
Mydriasis	20.72	12.73	27	27750	6116	29918585
Cardiac failure congestive	20.53	12.73	29	27748	84378	29840323
Neuromuscular blockade	20.30	12.73	7	27770	149	29924552
Parkinsonism	20.06	12.73	29	27748	7240	29917461
Weight increased	20	12.73	24	27753	74889	29849812
Appendicitis perforated	19.92	12.73	15	27762	1743	29922958
Disease progression	19.86	12.73	27	27750	79847	29844854
Illusion	19.82	12.73	11	27766	757	29923944
Therapeutic product effect prolonged	19.52	12.73	8	27769	278	29924423
Neuropathy peripheral	19.44	12.73	22	27755	70453	29854248
Procedural hypotension	19.38	12.73	12	27765	1013	29923688
Drug resistance	18.94	12.73	51	27726	20082	29904619
Hypoglycaemia	18.85	12.73	12	27765	50969	29873732
Periorbital swelling	18.74	12.73	7	27770	189	29924512
Encephalopathy	18.67	12.73	69	27708	32136	29892565
Postresuscitation encephalopathy	18.66	12.73	4	27773	11	29924690
Overdose	18.64	12.73	138	27639	84199	29840502
Mumps	18.44	12.73	6	27771	106	29924595
Pseudomonal sepsis	18.40	12.73	18	27759	2982	29921719
Cardiogenic shock	18.22	12.73	45	27732	16816	29907885
Electrocardiogram QRS complex prolonged	17.97	12.73	21	27756	4256	29920445
Heart alternation	17.95	12.73	3	27774	0	29924701
Chest pain	17.88	12.73	53	27724	117574	29807127
Nerve block	17.72	12.73	4	27773	15	29924686
Pneumomediastinum	17.51	12.73	14	27763	1777	29922924
Staring	17.50	12.73	13	27764	1480	29923221
Conversion disorder	17.43	12.73	8	27769	367	29924334
Bronchospasm	17.39	12.73	33	27744	10305	29914396
Aggression	17.31	12.73	74	27703	36833	29887868
Asthma	17.23	12.73	6	27771	36168	29888533
Paraesthesia	17.23	12.73	15	27762	54312	29870389
Victim of homicide	17.22	12.73	6	27771	132	29924569
Methaemoglobinaemia	17.17	12.73	16	27761	2494	29922207
Suspiciousness	17.15	12.73	8	27769	381	29924320
Respiratory disorder	17.15	12.73	45	27732	17449	29907252
Upper airway obstruction	17.01	12.73	9	27768	563	29924138
Opisthotonus	16.98	12.73	8	27769	390	29924311
Pulse absent	16.84	12.73	23	27754	5450	29919251
Musculoskeletal pain	16.82	12.73	4	27773	30936	29893765
Abdominal pain upper	16.74	12.73	20	27757	62531	29862170
Cerebral ventricle dilatation	16.73	12.73	10	27767	792	29923909
Tonic clonic movements	16.61	12.73	11	27766	1043	29923658
Blood creatine phosphokinase MB increased	16.43	12.73	14	27763	1942	29922759
Dyspepsia	16.34	12.73	4	27773	30325	29894376
Arthrofibrosis	16.19	12.73	5	27772	74	29924627
Periventricular haemorrhage neonatal	16.18	12.73	4	27773	24	29924677
Ventricular extrasystoles	16.15	12.73	34	27743	11440	29913261
Haematuria traumatic	16.03	12.73	6	27771	163	29924538
Product contamination	15.95	12.73	9	27768	640	29924061
Intensive care	15.95	12.73	7	27770	289	29924412
Abdominal compartment syndrome	15.87	12.73	10	27767	871	29923830
Fear of death	15.83	12.73	9	27768	649	29924052
Drug withdrawal syndrome neonatal	15.75	12.73	17	27760	3158	29921543
Constipation	15.67	12.73	53	27724	112853	29811848
Post procedural haemorrhage	15.53	12.73	27	27750	7883	29916818
Clonus	15.43	12.73	15	27762	2466	29922235
Distractibility	15.32	12.73	7	27770	318	29924383
Automatism	15.23	12.73	5	27772	91	29924610
Acute pulmonary oedema	15.21	12.73	26	27751	7489	29917212
Catheter site haemorrhage	15.16	12.73	14	27763	2158	29922543
Administration related reaction	15.13	12.73	5	27772	93	29924608
Sinusitis	15.10	12.73	6	27771	33339	29891362
Partial seizures	15.01	12.73	18	27759	3749	29920952
Completed suicide	15.00	12.73	45	27732	99447	29825254
Neutropenia	14.84	12.73	65	27712	128475	29796226
Product measured potency issue	14.84	12.73	5	27772	99	29924602
Cellulitis	14.74	12.73	13	27764	46771	29877930
Pulmonary oedema	14.71	12.73	80	27697	43895	29880806
Cerebrovascular accident	14.66	12.73	35	27742	83442	29841259
Mucosal inflammation	14.63	12.73	5	27772	30489	29894212
Urinary tract infection	14.49	12.73	29	27748	73630	29851071
Electrocardiogram P wave abnormal	14.43	12.73	5	27772	108	29924593
Coronary artery disease	14.28	12.73	15	27762	49697	29875004
Pneumothorax	14.22	12.73	40	27737	16153	29908548
Large intestine anastomosis	14.21	12.73	4	27773	42	29924659
Fluid retention	14.06	12.73	3	27774	24995	29899706
Hepatitis	13.89	12.73	49	27728	22307	29902394
Angina pectoris	13.88	12.73	5	27772	29513	29895188
Postoperative delirium	13.88	12.73	4	27773	46	29924655
Systemic inflammatory response syndrome	13.71	12.73	23	27754	6523	29918178
Myotonia	13.65	12.73	4	27773	49	29924652
Low birth weight baby	13.61	12.73	22	27755	6054	29918647
Cardiac procedure complication	13.55	12.73	6	27771	253	29924448
Airway complication of anaesthesia	13.53	12.73	5	27772	131	29924570
Orthostatic hypotension	13.24	12.73	3	27774	23976	29900725
Muscle spasms	13.21	12.73	25	27752	64813	29859888
Nervous system disorder	13.20	12.73	34	27743	13035	29911666
Glossoptosis	13.18	12.73	5	27772	141	29924560
Hyperbilirubinaemia	13.10	12.73	40	27737	16902	29907799
Heart rate decreased	13.03	12.73	46	27731	20948	29903753
Non-cardiogenic pulmonary oedema	12.86	12.73	8	27769	681	29924020
Post procedural haematoma	12.84	12.73	11	27766	1536	29923165
Hypoaesthesia	12.81	12.73	19	27758	54211	29870490
Mean arterial pressure decreased	12.77	12.73	5	27772	154	29924547
Heparin-induced thrombocytopenia	12.75	12.73	20	27757	5363	29919338
Thrombophlebitis superficial	12.74	12.73	14	27763	2655	29922046

Pharmacologic Action:

Source	Code	Description
ATC	N05CD08	NERVOUS SYSTEM PSYCHOLEPTICS HYPNOTICS AND SEDATIVES Benzodiazepine derivatives
FDA CS	M0002356	Benzodiazepines
MeSH PA	D000759	Adjuvants, Anesthesia
MeSH PA	D000777	Anesthetics
MeSH PA	D018686	Anesthetics, Intravenous
MeSH PA	D014151	Anti-Anxiety Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D018682	GABA Agents
MeSH PA	D018757	GABA Modulators
MeSH PA	D006993	Hypnotics and Sedatives
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
FDA EPC	N0000175694	Benzodiazepine
CHEBI has role	CHEBI:35474	minor tranquilisers
CHEBI has role	CHEBI:35488	cns depressants
CHEBI has role	CHEBI:35610	cytostatic
CHEBI has role	CHEBI:35623	antiepileptic
CHEBI has role	CHEBI:35717	sedatives
CHEBI has role	CHEBI:38869	general anaesthetic
CHEBI has role	CHEBI:51371	muscle relaxants
CHEBI has role	CHEBI:68495	type i programmed cell-death inducer
CHEBI has role	CHEBI:91016	gabaa receptor agonists

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Feeling agitated	indication	24199005
Anxiety	indication	48694002
General anesthesia	indication	50697003
Sedation	indication	72641008
Conscious sedation	indication	314271007
Local anesthesia	indication	386761002
Sedation as Adjunct to Anesthesia	indication
Induce Anterograde Amnesia	indication
Sedation in Intubated Patients	indication
Preoperative Anxiety	indication
Insomnia	off-label use	193462001
Status epilepticus	off-label use	230456007	DOID:1824
Cocaine-Associated Acute Ischemic Heart Disease	off-label use
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Cirrhosis of liver	contraindication	19943007	DOID:5082
Shock	contraindication	27942005
End stage renal disease	contraindication	46177005	DOID:784
Chronic heart failure	contraindication	48447003
Pregnancy, function	contraindication	289908002
Coma	contraindication	371632003
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Hemodynamic instability	contraindication	422773005
Peripheral Vasoconstriction	contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	6.07	Basic
pKa2	2.36	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
5MG/SPRAY	NULLYZILAM	UCB INC	N211321	May 17, 2019	RX	SPRAY	NULLSAL	May 21, 2022	NEW PRODUCT
EQ 50MG BASE/10ML (EQ 5MG BASE/ML)	SEIZALAM	MERIDIAN MEDCL TECHN	N209566	Sept. 14, 2018	RX	SOLUTION	INTRAMUSCULAR	Sept. 14, 2025	TREATMENT OF STATUS EPILEPTICUS IN ADULTS
5MG/SPRAY	NULLYZILAM	UCB INC	N211321	May 17, 2019	RX	SPRAY	NULLSAL	May 17, 2026	ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
GABA-A receptor alpha-1/beta-2/gamma-2	Ion channel	P14867 P18507 P47870	GBRA1_HUMAN GBRB2_HUMAN GBRG2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.74		WOMBAT-PK	CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2	Ion channel	P18507 P34903 P47870	GBRA3_HUMAN GBRB2_HUMAN GBRG2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.44		WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-3/gamma-3	Ion channel	P28472 P31644 Q99928	GBRA5_HUMAN GBRB3_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.26		WOMBAT-PK	CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2	Ion channel	P18507 P28472 P31644	GBRA5_HUMAN GBRB3_HUMAN GBRG2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.12		WOMBAT-PK	CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3	Ion channel	P34903 P47870 Q99928	GBRA3_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	7.61		WOMBAT-PK	CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3	Ion channel	P14867 P47870 Q99928	GBRA1_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	7.75		WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2	Ion channel	P18507 P31644 P47870	GBRA5_HUMAN GBRB2_HUMAN GBRG2_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	9.12		WOMBAT-PK	CHEMBL
GABA A receptor alpha-5/beta-2/gamma-3	Ion channel	P31644 P47870 Q99928	GBRA5_HUMAN GBRB2_HUMAN GBRG3_HUMAN	POSITIVE ALLOSTERIC MODULATOR	Ki	8.26		WOMBAT-PK	CHEMBL
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Km	4.35		WOMBAT-PK
Cytochrome P450 3A4	Enzyme	P08684	CP3A4_HUMAN		Km	6		WOMBAT-PK
Thyrotropin-releasing hormone receptor	GPCR		TRFR_RAT	ANTAGONIST	Ki	5.49		IUPHAR
GABA-A receptor; anion channel	Ion channel		GBRA1_RAT GBRA2_RAT GBRA3_RAT GBRA4_RAT GBRA5_RAT GBRA6_RAT GBRB1_RAT GBRB2_RAT GBRB3_RAT GBRD_RAT GBRE_RAT GBRG1_RAT GBRG2_RAT GBRG3_RAT GBRP_RAT Q91ZM7_RAT		Ki	8.70		CHEMBL
Translocator protein	Membrane receptor		TSPO_RAT		Ki	8.70		CHEMBL

External reference:

ID	Source
4019839	VUID
N0000147927	NUI
D00550	KEGG_DRUG
59467-96-8	SECONDARY_CAS_RN
4017813	VANDF
4019839	VANDF
C0026056	UMLSCUI
CHEBI:6932	CHEBI
08J	PDB_CHEM_ID
CHEMBL1200420	ChEMBL_ID
CHEMBL655	ChEMBL_ID
D008874	MESH_DESCRIPTOR_UI
DB00683	DRUGBANK_ID
4192	PUBCHEM_CID
3342	IUPHAR_LIGAND_ID
4497	INN_ID
R60L0SM5BC	UNII
203128	RXNORM
130935	MMSL
24970	MMSL
32073	MMSL
5114	MMSL
d00301	MMSL
001467	NDDF
004585	NDDF
26800000	SNOMEDCT_US
373476007	SNOMEDCT_US
84213009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0054-3566	SYRUP	2 mg	ORAL	ANDA	25 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2305	INJECTION, SOLUTION	1 mg	INTRAMUSCULAR	ANDA	29 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2305	INJECTION, SOLUTION	1 mg	INTRAMUSCULAR	ANDA	29 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2306	INJECTION, SOLUTION	1 mg	INTRAMUSCULAR	ANDA	29 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2307	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	ANDA	29 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2308	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	ANDA	29 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2308	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	ANDA	29 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2587	INJECTION, SOLUTION	1 mg	INTRAMUSCULAR	ANDA	28 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0409-2596	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	ANDA	28 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0574-0150	SYRUP	2 mg	ORAL	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6056	INJECTION	1 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6057	INJECTION	1 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6059	INJECTION	1 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6060	INJECTION	5 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6061	INJECTION	5 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6063	INJECTION	5 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6190	INJECTION	5 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6209	INJECTION	1 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6210	INJECTION	1 mg	INTRAMUSCULAR	ANDA	27 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6211	INJECTION	5 mg	INTRAMUSCULAR	ANDA	27 sections
Seizalam	HUMAN PRESCRIPTION DRUG LABEL	1	11704-650	INJECTION, SOLUTION	5 mg	INTRAMUSCULAR	NDA	32 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	17478-523	INJECTION	1 mg	INTRAVENOUS	ANDA	28 sections
Midazolam	HUMAN PRESCRIPTION DRUG LABEL	1	17478-524	INJECTION	5 mg	INTRAVENOUS	ANDA	28 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0146	SYRUP	2 mg	ORAL	ANDA	27 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	17856-0205	SYRUP	2 mg	ORAL	ANDA	25 sections
Midazolam Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	17856-3566	SYRUP	2 mg	ORAL	ANDA	24 sections
Midazolam hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	23155-600	INJECTION, SOLUTION	1 mg	INTRAMUSCULAR	ANDA	24 sections
Midazolam hydrochloride	Human Prescription Drug Label	1	23155-601	INJECTION, SOLUTION	5 mg	INTRAVENOUS	ANDA	24 sections
MIDAZOLAM HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-610	INJECTION, SOLUTION	1 mg	INTRAVENOUS	NDA	30 sections
MIDAZOLAM HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	44567-611	INJECTION, SOLUTION	1 mg	INTRAVENOUS	NDA	30 sections